NEW YORK (GenomeWeb News) – Arca biopharma today said that Laboratory Corporation of America has told it that the US Food and Drug Administration has accepted LabCorp's investigational device exemption application for a companion diagnostic test for an atrial fibrillation drug under development.

The test is for use with Arca's Gencaro (bucindolol hydrochloride), a beta blocker and mild vasodilator, and the IDE allows the test to be used in a planned clinical trial for the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns. 

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy. 

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.